Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from a $1.6B valuation in May 2025 (Katherine Davis/Axios)
Techmemeen
Katherine Davis / Axios : Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from a $1.6B valuation in May 2025 — Precision oncology biotech Pathos AI said Friday it raised a $237 million Series E round at a $3 billion post-money valuation.
This is a short summary published by AI Global Wire. The full article is owned and hosted by Techmeme — open it there to read it in full.
Read the full story at Techmeme- Företag
Related AI news
- OpenAI lowers valuation target, raises up to $30 billionThe Decoder · October 23, 2026
- OpenAI is closing in on a new funding round with UAE investorsThe Decoder · October 23, 2026
- SK Hynix shares jump over 4% after early losses as chipmaker scraps Solidigm IPO plansCNBC Technology · October 23, 2026
- Commentary: How long can the humanoid robot bubble last? Unitree's valuation correction puts physical AI to the testDIGITIMES · October 23, 2026
- SK Hynix says its SSD subsidiary Solidigm has halted a review of a potential US IPO to fund a new US chip fab, citing "market conditions and share price trends" (P.R. Venkat/Wall Street Journal)Techmeme · October 23, 2026
- Visa prepara su identidad visual para un mundo donde la inteligencia artificial también compraInteligencia artificial (ES) · October 23, 2026